Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended

2023-503235-18-00 previously untreated WM 4 2024-01-31
FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatme… Ended

2022-501372-25-00 Patients aged 18 years and older with relapsed or refra 4 2024-01-10
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Higher-risk myelodysplastic syndromes untreated and ine 9 2023-12-06
Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD Ended

2023-505053-40-00 Multiple Myeloma 4 2023-11-30
An open label, multicenter, phase II study of Elranatamab as single agent for the treatment of relapsed or refractory myeloma in patients pr… Ended

2023-504273-21-00 Multiple Myeloma 4 2023-10-31
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended

2024-514878-53-00 HMA-naïve, higher-risk (HR, defined as CPSS-mol risk in 4 2023-10-04
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841) Ended

2022-500100-21-01 Follicular lymphoma 4 2023-09-11
An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as ma… Ended

2024-514527-42-00 Multiple myeloma 4 2023-07-28
HOVON 164 HL: Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma followed by Tislelizumab Consolidation… Ended

2022-502225-17-00 Hodgkin lymphoma 4 2023-07-14
AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended

2024-515479-36-00 Chronic Myeloid Leukemia 5 2023-07-05
An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab… Ended

2024-514016-26-00 Multiple Myeloma 4 2023-06-22
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablurs… Ended

2024-512482-14-00 Polycythemia Vera 4 2023-06-21
Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBC… Ended

2024-516929-31-00 Patients affected by relapsed/refractory DLBCL or HGBCL 4 2023-06-19
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with ritu… Ended

2024-512390-27-00 Relapsed/refractory CD20 positive B-cell Non-Hodgkin's 1 2023-06-09
Long-Term Follow-Up (LTFU) for Gene Therapy of Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infu… Ended

2022-501526-38-00 Pyruvate kinase deficiency 3 2023-06-06
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed K… Ended

2022-502275-39-00 multiple myeloma 9 2023-05-19
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Ended

2022-500721-32-01 AML and MDS patients failing or being refractory to hyp 4 2023-05-03
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas… Ended

2023-503444-13-00 Relapsed/refractory multiple myeloma 5 2023-03-29
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Primary immune thrombocytopenia (ITP) 5 2023-03-20
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 previously untreated aggressive B-cell lymphoma 4 2023-03-16
CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti… Ended

2024-514345-11-00 children, adolescents and young adults with Acute Lymph 9 2023-03-15
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended

2022-500861-29-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2023-01-12